RobertAlanNagourneyMD

Oncology • Long Beach, CA

Hematologic Oncology

Founder & Medical Director of Rational Therapeutics

Join to view full profile

Dr. Nagourney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Nagourney's full profile

Already have an account?

Office
701 E 28th St
Ste 418
Long Beach, CA 90806
Phone+1 562-997-4070

Fax+1 562-997-4090
Is this information wrong?

Education & Training

Scripps Clinic/Scripps Green HospitalFellowship, Hematology and Medical Oncology, 1984 - 1985
Georgetown University HospitalFellowship, Medical Oncology, 1982 - 1984
University of California (Irvine)Residency, Internal Medicine, 1980 - 1982
McGill University Faculty of MedicineClass of 1979

Certifications & Licensure

CA State Medical License 1980 - 2025
VA State Medical License 1983 - 2022
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Publications & Presentations

PubMed

Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants.
Adam J Nagourney, Joshua B Gipoor, Steven S Evans, Paulo D'Amora, Paula J Bernard, Federico Francisco, Robert A Nagourney, Duesberg, M.> ;Genes. 2023 Mar 19
7 citations
Platinum resistance in gynecologic malignancies: Response, disease free and overall survival are predicted by biochemical signature: A metabolomic analysis.
Paulo D'Amora, Ismael Dale Cotrim Guerreiro da Silva, Krishnansu S. Tewari, Robert E. Bristow, Fabio Cappuccini, Steven S. Evans, Marcia Batista Salzgeber, Paula J. Ad...> ;Gynecologic Oncology. 2021 Oct 1
10 citations
Towards risk stratification and prediction of disease severity and mortality in COVID-19: Next generation metabolomics for the measurement of host response to COVID-19...
Paulo D'Amora, Ismael Dale C. G. Silva, Maria Auxiliadora Budib, Ricardo Ayache, Rafaela Moraes Siufi Silva, Fabricio Colacino Silva, Robson Mateus Appel, Saturnino Sa...> ;Plos One. 2021 Jan 1
39 citations
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
Robert A. Nagourney, Steven S. Evans, Peter Tran, Adam J. Nagourney, Paul H. Sugarbaker> ;European Journal of Surgical Oncology. 2021 Apr 1
Metastatic carcinoma of unknown primary with complete metabolic response following sorafenib-based chemotherapy.
Pedro Luiz Serrano Uson Junior, Jairo Wagner, Marcus Vinicius de Nigro Corpa, Iracema Moraes Coelho, Robert A. Nagourney, Nise Hitomi Yamaguchi> ;SAGE Open Medical Case Reports. 2019 Mar 21
9 citations
Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality
Ismael Dale Cotrim Guerreiro da Silva, Rene da Costa Vieira, Carolina Stella, Edson Guimaraes Loturco, André Lopes Carvalho, Carlos Veo, Cristovam Scapulatempo Neto, S...> ;Oncotarget. 2018 Aug 3
17 citations
Multifocal Breast Cancer in Young Women with Prolonged Contact between Their Breasts and Their Cellular Phones.
John G. West, Nimmi S. Kapoor, Shu-Yuan Liao, June W. Chen, Lisa Bailey, Robert A. Nagourney> ;Case Reports in Medicine. 2013 Sep 18
Sheldon S. Hendler, PhD, MD (1936-2012).
Joyce Hendler, Ross Hendler, Robert A. Nagourney, Mary Ann Liebert> ;Journal of Medicinal Food. 2012 Dec 1
12 citations
Functional Profiling to Select Chemotherapy in Untreated, Advanced or Metastatic Non-small Cell Lung Cancer
Robert A. Nagourney, Jonathan B. Blitzer, Robert L. Shuman, Thomas J. Asciuto, Eknath A. Deo, Marylyn Paulsen, Robert L. Newcomb, Steve S. Evans> ;Anticancer Research. 2012 Oct 1
Functional analysis of PARP inhibitors AZD 2281 and BSI-201 in human tumor primary cultures: A comparison of activity and examination of synergy with cytotoxic drugs.
Nagourney RA, Kenyon KR, Francisco FR, Bernard PJ, Evans SS> ;J. Clin. Oncol.. 2011-05-20
253 citations
An RNAi-based chemical genetic screen identifies three small-molecule inhibitors of the Wnt/wingless signaling pathway
Foster C. Gonsalves, Keren Klein, Brittany Carson, Shauna Katz, Laura A. Ekas, Steve S. Evans, Robert A. Nagourney, Timothy Cardozo, Anthony M. C. Brown, Ramanuj DasGupta> ;Proceedings of the National Academy of Sciences of the United States of America. 2011 Apr 12
19 citations
Medicinal Food Meets Epigenetics
Robert A. Nagourney, Sheldon S. Hendler> ;Journal of Medicinal Food. 2011 Jan 18
Functional profiling in stage IV NSCLC: A phase II trial of individualized therapy.
Nagourney RA, Blitzer J, Deo E, Nandan R, Schuman R, Asciuto T, Mc Connell D, Paulsen M, Evans S> ;J. Clin. Oncol.. 2009-05-20
Functional profiling in stage IV colorectal cancer: A phase II trial of individualized therapy.
Blitzer JB, Shbeeb I, Neoman A, Azaren K, Paulsen M, Evans S, Nagourney R> ;J. Clin. Oncol.. 2009-05-20
17 citations
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer.
Robert A. Nagourney, Marshall Flam, John S. Link, Steven Hager, Jonathan B. Blitzer, William Lyons, Barbara L. Sommers, Steven S. Evans> ;Clinical Breast Cancer. 2008 Oct 1
Clinical application of functional profiling in advanced NSCLC and colorectal cancers.
Nagourney RA, Blitzer J, McConnell D, Shuman R, Grant S, Azaren K, Shbeeb I, Ascuito T, Sommers B, Paulsen M> ;J. Clin. Oncol.. 2008-05-20
49 citations
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, Mark A. Morgan, Parviz Hanjani> ;Gynecologic Oncology. 2006 Nov 1
29 citations
Ex vivo programmed cell death and the prediction of response to chemotherapy.
Robert A. Nagourney> ;Current Treatment Options in Oncology. 2006 Mar 1
32 citations
Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Cheryl A. Brewer, John A. Blessing, Robert A. Nagourney, D. Scott McMeekin, Shashikant Lele, Susan Zweizig> ;Gynecologic Oncology. 2006 Feb 1
Casting-type calcification breast cancer: Assessment of response to cytotoxic insult in human tumor primary culture spheroids.
Nagourney RA, Sommers B, Evans S, Kollin C, Su YZ, Evans T, Islas J, Kakkis J, Tabar L> ;J. Clin. Oncol.. 2005-06-01
Assay directed chemotherapy in advanced solid tumors: A phase II trial.
Blitzer JB, Mc Connell D, Cullinane C, Grant S, Asciuto T, Shbeeb I, Sommers B, Jacobs C, Davis S, Byczynski K, Nagourney R> ;J. Clin. Oncol.. 2005-06-01
7 citations
Chemosensitivity and resistance assays: a systematic review?
R. A. Nagourney> ;Journal of Clinical Oncology. 2005 May 20
Carboplatin & gemcitabine repeating doublet in recurrent breast cancer.
Nagourney RA, Link J, Sommers B, Lyons W, Blitzer J, Hager S, Flam M> ;J. Clin. Oncol.. 2004-07-15
73 citations
Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.
Robert A. Nagourney, Cheryl A. Brewer, Stephen E. Radecki, Wesley A. Kidder, Barbara L. Sommers, Steven S. Evans, David R. Minor, Philip J. DiSaia> ;Gynecologic Oncology. 2003 Jan 1
65 citations
Herbal Composition PC-SPES for Management of Prostate Cancer: Identification of Active Principles
Milos Sovak, Allen L. Seligson, Martin Konas, Marian Hajduch, Marek Dolezal, Miroslav Machala, Robert A. Nagourney> ;Journal of the National Cancer Institute. 2002 Sep 4
Join now to see all

Press Mentions

Blood Test Could Identify Severity of SARS-CoV-2 Infections, Researchers SayDecember 12th, 2021
Radiation from Wireless Devices May Cause Breast Cancer, New Study ShowsDecember 17th, 2020
Maria LewisJuly 31st, 2019
Join now to see all